Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453985 | 0.95 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL7902218 | 0.95 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL8102931 | 0.93 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL8110849 | 0.93 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL8112485 | 0.92 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL8117682 | 0.92 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL956031 | 0.92 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL8103055 | 0.90 | ALDH1A1 (0.47) | ALDH1A1 | |
| Fumaric Acid SCHEMBL956029 | 0.89 | — | — | |
| SCHEMBL8111916 | 0.88 | ALDH1A1 (0.54) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906919-B2 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | OZTEO PTY LTD (AU) | 2014-12-09 | — | — | US | claimed |
| US-20120172363-A1 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | Ozleo Pty Ltd (AU) | 2012-07-05 | — | — | US | claimed |
| US-6191281-B1 | CRYSTALS OF A SALT OF (S)-(-)-2-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)-3-(3-(N-METHYL-N -(2-(3,4-METHYLENEDIOXYPHENOXY)ETHYL)AMINO)PROPYL)-1, 3-THIAZOLIDINE-4-ONE, USEFUL AS ANTIISCHEMIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-02-20 | — | — | US | claimed |
| EP-0974591-A1 | CRYSTALLINE FUMARATE OF 2-PHENYL-1,3-THIAZOLIDINE-4-ON DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-01-26 | — | — | EP | claimed |
| US-8906919-B2 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | OZTEO PTY LTD (AU) | 2014-12-09 | — | — | US | disclosed |
| US-20120172363-A1 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | Ozleo Pty Ltd (AU) | 2012-07-05 | — | — | US | disclosed |
| EP-2453893-A1 | TREATMENT OF NON-NEURONAL AND NON-MYOCARDIAL CELL, TISSUE AND ORGAN DAMAGE AND ASSOCIATED PAIN WITH PERSISTENT SODIUM CURRENT BLOCKERS | Ozteo Pty Ltd (AU) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011003129-A1 | TREATMENT OF NON-NEURONAL AND NON-MYOCARDIAL CELL, TISSUE AND ORGAN DAMAGE AND ASSOCIATED PAIN WITH PERSISTENT SODIUM CURRENT BLOCKERS | OZTEO PTY LTD (AU) | 2011-01-13 | — | — | WO | disclosed |
| US-6191281-B1 | CRYSTALS OF A SALT OF (S)-(-)-2-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)-3-(3-(N-METHYL-N -(2-(3,4-METHYLENEDIOXYPHENOXY)ETHYL)AMINO)PROPYL)-1, 3-THIAZOLIDINE-4-ONE, USEFUL AS ANTIISCHEMIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-02-20 | — | — | US | disclosed |
| EP-0974591-A1 | CRYSTALLINE FUMARATE OF 2-PHENYL-1,3-THIAZOLIDINE-4-ON DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172363-A1 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers | TNNI3, TNNC1, HCN4 | ALDH1A1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.